The Problem
The Aging Crisis
Is Not Coming.
It Is Here.
"The global population is aging at a rate that no healthcare system in the world was designed to handle. The question is no longer whether we face a crisis — it is whether we have the science to respond to it."
— BICC Research Brief, 2025
The Numbers
The Scale of the
Problem.
2.1B
People aged 60+ by 2050
DOUBLE TODAY'S FIGURE
WHO, 2023
80%
Adults 65+ with chronic disease
AT LEAST ONE CONDITION
CDC, 2022
$7.1T
Annual cost of aging by 2025
GLOBAL ECONOMIC BURDEN
AARP, 2023
16%
Global population aged 65+ by 2050
UP FROM 9% TODAY
UN, 2023
The Disease Burden
The Diseases of Aging
Are Largely Preventable..
The majority of age-related chronic diseases share a common root cause: cellular dysfunction driven by oxidative stress, mitochondrial decline, and systemic inflammation. BICC's science addresses these mechanisms at the source.
DISEASE | PREVALENCE IN 65+ | TREND | ECONOMIC IMPACT |
|---|---|---|---|
Cardiovascular Disease | 47% | Rising | Leading cause of death globally |
Type 2 Diabetes | 29% | Rising | $327B annual US cost alone |
Neurodegenerative Disease | 14% | Accelerating | No disease-modifying treatment |
Musculoskeletal Disorders | 52% | Rising | Leading cause of disability |
Metabolic Syndrome | 40% | Rising | Precursor to multiple diseases |
Immune Dysfunction | 35% | Rising | Increased infection vulnerability |
The Trajectory
A Crisis on a
Schedule
2025
Global 60+ population reaches 1.4 billion
2030
1 in 6 people worldwide will be over 60
2035
Healthcare systems in 40+ countries face
insolvency risk
2040
Dementia cases projected to triple vs.
2020 baseline
2050
2.1 billion people aged 60+ — double
today's figure
The Opportunity
The Longevity Economy
Is the Largest Market of Our Lifetime.
Every crisis creates a market. The aging crisis is creating the largest health and wellness market in human history. BICC is positioned at the intersection of the highest-growth segments.
Longevity Nutraceuticals
$340B
+8.9% CAGR by 2025
Regenerative Medicine
$68B
+15.4% CAGR by 2025
Stem Cell Therapy
$17.9B
+12.8% CAGR by 2025
EV / Exosome Therapy
$2.8B
+28.6% CAGR by 2026
Anti-Aging Skincare
$93B
+6.2% CAGR by 2025
Precision Medicine
$96B
+11.5% CAGR by 2025